X
[{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satellos Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Satellos Bioscience
Filters
Companies By Therapeutic Area
Details:
SAT-3247 is a small molecule designed to inhibit AAK1, a protein kinase member of the notch pathway. It is being developed for the treatment of facioscapulohumeral muscular dystrophy.
Lead Product(s):
SAT-3247
Therapeutic Area: Musculoskeletal
Product Name: SAT-3247
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 13, 2024
Details:
SAT-3247 as lead drug candidate that target AAK1, a protein kinase, which is investigated for the treatment of Duchenne Muscular Dystrophy. The patent applications for its drug target and drug development candidates, and remains on track to initiate clinical development in mid-2024.
Lead Product(s):
SAT-3247
Therapeutic Area: Genetic Disease
Product Name: SAT-3247
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 14, 2023